Accordingly, we conjectured that the missense variants rs1799966 may hinder the performance of BRCA1 in the above biological process thus conferring pancreatic cancer patients in different genotypes with different risk of deterioration and survival time. This evidence concerns the gene BRCA1 and familial pancreatic carcinoma.